Agenus (NASDAQ:AGEN) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Agenus (NASDAQ:AGEN) from a hold rating to a buy rating in a report released on Saturday morning, ValuEngine reports.

Several other brokerages have also recently commented on AGEN. B. Riley assumed coverage on shares of Agenus in a research note on Friday, December 20th. They set a buy rating and a $6.00 price objective for the company. BidaskClub cut shares of Agenus from a hold rating to a sell rating in a research note on Wednesday, January 8th.

Shares of NASDAQ AGEN opened at $3.90 on Friday. Agenus has a 12 month low of $2.13 and a 12 month high of $4.57. The company has a 50 day simple moving average of $3.89 and a two-hundred day simple moving average of $3.15. The stock has a market cap of $541.20 million, a price-to-earnings ratio of -3.94 and a beta of 2.09.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.05. The business had revenue of $19.94 million for the quarter, compared to analyst estimates of $15.60 million. Sell-side analysts forecast that Agenus will post -0.97 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in shares of Agenus by 11.0% in the 2nd quarter. BlackRock Inc. now owns 9,294,627 shares of the biotechnology company’s stock valued at $27,884,000 after purchasing an additional 919,105 shares during the period. Vanguard Group Inc. lifted its stake in shares of Agenus by 16.7% in the 2nd quarter. Vanguard Group Inc. now owns 5,540,211 shares of the biotechnology company’s stock valued at $16,620,000 after purchasing an additional 793,180 shares during the period. State Street Corp lifted its stake in shares of Agenus by 14.8% in the 3rd quarter. State Street Corp now owns 2,399,958 shares of the biotechnology company’s stock valued at $6,192,000 after purchasing an additional 309,954 shares during the period. Northern Trust Corp lifted its stake in shares of Agenus by 0.9% in the 2nd quarter. Northern Trust Corp now owns 1,167,016 shares of the biotechnology company’s stock valued at $3,501,000 after purchasing an additional 10,663 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Agenus by 7.8% in the 2nd quarter. Wells Fargo & Company MN now owns 875,671 shares of the biotechnology company’s stock valued at $2,627,000 after purchasing an additional 63,196 shares during the period. Hedge funds and other institutional investors own 35.72% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Further Reading: What Does a Sell-Side Analyst Rating Mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.